{"id_": "1329044798045622274", "raw_data": {"created_at": "Wed Nov 18 12:52:26 +0000 2020", "id": 1329044798045622274, "id_str": "1329044798045622274", "full_text": "TOP!!!! Gratulation nach Mainz!\n⁦@BioNTech_Group⁩ Impfstoff Studie  erfolgreich beendet mit 95% (!!!!) Wirksamkeit, auch bei Älteren. Somit genauso wirksam Moderna Impfstoff. Die schlechteste Woche für SarsCoV seit Pandemiebeginn.   https://t.co/BTgKZIQDI6", "truncated": false, "display_text_range": [0, 256], "entities": {"hashtags": [], "symbols": [], "user_mentions": [{"screen_name": "BioNTech_Group", "name": "BioNTech SE", "id": 1060984350995550208, "id_str": "1060984350995550208", "indices": [33, 48]}], "urls": [{"url": "https://t.co/BTgKZIQDI6", "expanded_url": "https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine/", "display_url": "investors.biontech.de/news-releases/…", "indices": [233, 256]}]}, "source": "<a href=\"http://twitter.com/download/iphone\" rel=\"nofollow\">Twitter for iPhone</a>", "in_reply_to_status_id": null, "in_reply_to_status_id_str": null, "in_reply_to_user_id": null, "in_reply_to_user_id_str": null, "in_reply_to_screen_name": null, "user_id": 3292982985, "user_id_str": "3292982985", "geo": null, "coordinates": null, "place": null, "contributors": null, "is_quote_status": false, "retweet_count": 594, "favorite_count": 6709, "reply_count": 182, "quote_count": 110, "conversation_id": 1329044798045622274, "conversation_id_str": "1329044798045622274", "favorited": false, "retweeted": false, "possibly_sensitive": false, "possibly_sensitive_editable": true, "card": {"name": "summary", "url": "https://t.co/BTgKZIQDI6", "card_type_url": "http://card-type-url-is-deprecated.invalid", "binding_values": {"vanity_url": {"type": "STRING", "string_value": "investors.biontech.de", "scribe_key": "vanity_url"}, "domain": {"type": "STRING", "string_value": "investors.biontech.de"}, "title": {"type": "STRING", "string_value": "Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary..."}, "description": {"type": "STRING", "string_value": "Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose; 170 confirmed cases of COVID-19 were evaluated, with 162 observed in the..."}, "card_url": {"type": "STRING", "string_value": "https://t.co/BTgKZIQDI6", "scribe_key": "card_url"}}, "card_platform": {"platform": {"device": {"name": "Swift", "version": "12"}, "audience": {"name": "production", "bucket": null}}}}, "lang": "de", "supplemental_language": null}}